Drug intelligence / Profile preview

826827

Development stage
Preclinical
Lead developer
Case Western Reserve University
Modality
Monoclonal Antibodies → Antibody-Based Therapeutics
Administration
Intravenous
01

Overview

826827 (also known as humAb 826827) is a fully human monoclonal antibody that targets the Apical Membrane Antigen 1 (AMA1) of *Plasmodium vivax* (PvAMA1). PvAMA1 is an essential invasion protein utilized by both sporozoites during hepatocyte invasion and merozoites during reticulocyte invasion. 826827 binds to highly conserved residues within the hydrophobic groove of PvAMA1, blocking its interaction with its native receptor, Rhoptry Neck Protein 2 (RON2). This dual-stage inhibition prevents both pre-erythrocytic (liver stage) and blood-stage infections. Developed collaboratively by academic and research institutions including Case Western Reserve University, the Walter and Eliza Hall Institute of Medical Research, and the Burnet Institute, 826827 has demonstrated potent strain-transcending inhibitory activity in vitro and significantly reduced liver parasite burden in humanized mouse models in vivo.

Other names
clone 826827clone826827clone-826827human anti-PvAMA1 recombinant antibody (clone 826827)
02

Targets

AMA1 (Apical membrane antigen 1)

Beyond the preview

Go deeper on 826827.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 826827.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call